2022-04-27 16:00Revenue and Profitability - Revenue for Q1 2022 reached ¥150,135,067.62, representing a significant increase of 3406.56% compared to the same period last year[4] - Net profit attributable to shareholders was -¥286,830,516.15, reflecting a decrease of 55.48% year-on-year[4] - The company reported a basic and diluted earnings per share of -¥0.59, a decrease of 56.91% year-on-year[6] - The net loss for Q1 2022 was ¥286,830,516.15, compared to a net loss of ¥184,482,710.79 in Q1 2021, representing an increase in losses of approximately 55.5%[22] - The total comprehensive loss for Q1 2022 was ¥287,615,486.11, compared to a loss of ¥184,491,494.35 in Q1 2021[23] Expenses and Costs - R&D expenses totaled ¥218,173,558.62, an increase of 60.29% compared to the previous year[6] - The gross profit margin was impacted by a significant increase in sales costs, which rose by 7585.76% due to the sales of new products[9] - The company reported a substantial increase in operating expenses, with sales expenses rising by 271.62% due to increased market development activities[9] - Total operating costs for Q1 2022 were ¥438,730,733.58, compared to ¥195,520,624.96 in Q1 2021, indicating a rise of approximately 124%[20] - The company incurred sales expenses of ¥80,784,391.23 in Q1 2022, significantly higher than ¥21,738,574.92 in Q1 2021, marking an increase of approximately 270%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,345,143,075.38, up 52.56% from the end of the previous year[6] - The company's cash and cash equivalents amounted to RMB 3,819,310,806.98, compared to RMB 1,835,498,496.42 in the same period last year, reflecting a growth of approximately 108.3%[16] - Total current assets reached RMB 4,389,341,093.64, up from RMB 2,299,951,998.84, indicating a year-over-year increase of about 91%[17] - The company's total liabilities were RMB 676,891,679.41, a decrease from RMB 712,787,425.02 in the previous year[18] - The equity attributable to shareholders of the parent company was RMB 5,668,251,395.97, compared to RMB 3,446,421,451.58 in the previous year, representing a growth of approximately 64.4%[19] Cash Flow - The net cash flow from operating activities was -¥350,478,067.32, a decrease of 29.06% compared to the previous year[6] - Cash flow from operating activities in Q1 2022 showed a net outflow of ¥350,478,067.32, worsening from a net outflow of ¥271,564,180.13 in Q1 2021[27] - The net cash flow from financing activities amounted to approximately ¥2.51 billion, after accounting for cash outflows of ¥120.36 million[28] - The total cash and cash equivalents at the end of the period reached ¥3.74 billion, an increase from the beginning balance of ¥1.76 billion[28] - The net increase in cash and cash equivalents for the period was approximately ¥1.98 billion[28] Shareholder Information - The company issued a total of 189,581,239 shares in Hong Kong, accounting for approximately 34.83% of the total share capital, and 354,681,764 shares on the Shanghai Stock Exchange, representing about 65.17%[13] - The top 10 shareholders held a significant portion of the company's shares, with HKSCC NOMINEES LIMITED holding approximately 96.52% of the Hong Kong shares[14] Future Plans and Developments - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[15] - The company is actively engaging in research and development of new technologies to enhance its competitive edge in the market[15] - The company launched new products, including injectable Taitasip and injectable Vidisimo monoclonal antibodies, contributing to revenue growth[9] Accounting Standards - The company did not apply the new accounting standards for the year 2022[29]